Ionis Pharmaceuticals (IONS)

Company Description

Ionis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. The company’s broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. IONS’ partner, Genzyme, plans to commercialize its lead product, Kynamro, in the U.S. and Europe following regulatory approval. IONS’ patents provide strong and extensive protection for its drugs and technology.

2855 Gazelle Court
Carlsbad, CA 92010
United States



Get BioInvest's perspective on Ionis Pharmaceutical's CEO

Latest Company News

AO Indicator Trending Lower For Ionis Pharmaceuticals Inc (IONS) FLBC News - 5 hours ago The Awesome Oscillator for Ionis Pharmaceuticals Inc (IONS) is showing a five day consistent downtrend, signaling building market momentum for the shares. [...]
Sat, Aug 19, 2017 12:11:00 AM, Continue reading at the source
2 Stocks to keep an eye on Today: Ionis Pharmaceuticals, Inc. (IONS), ACADIA ... StockNewsJournal - 17 hours ago Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) market capitalization at present is $5.85B at the rate of $47.15 a share. The firm's price-to-sales ratio was noted 12.14 in contrast with an overall industry average of 82.14. Trading Earnings Optimism With Options in Ionis Pharmaceuticals Inc - CML News [...]
Fri, Aug 18, 2017 11:26:00 AM, Continue reading at the source
Taking Aim at Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS) Shares Clayton News - Aug 18, 2017 Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS) has a Price to Book ratio of 26.974061. This ratio has been calculated by dividing the current share price by the book value per share. [...]
Fri, Aug 18, 2017 2:15:00 AM, Continue reading at the source
Active Stock on Watch: Ionis Pharmaceuticals Inc (IONS) Evergreen Caller - Aug 17, 2017 Needle moving action has been spotted in Ionis Pharmaceuticals Inc (IONS) as shares are moving today on volatility 1.12% or $0.53 from the open. [...]
Thu, Aug 17, 2017 3:11:00 PM, Continue reading at the source
Which Way Traders Signposts Ionis Pharmaceuticals, Inc. (IONS), Kura Oncology ... StockNewsJournal - Aug 14, 2017 ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business. Earnings Growth Research: Ionis Pharmaceuticals, Inc. (IONS), Kura Oncology ... - USA Commerce Daily [...]
Mon, Aug 14, 2017 3:56:00 PM, Continue reading at the source
Ionis Absorbs Glaxo Rare Disease Cull Seeking Alpha - Aug 14, 2017 From Ionis Pharmaceuticals' (NASDAQ:IONS) perspective, Glaxosmithkline's (NYSE:GSK) decision to opt out of its collaboration on inotersen and Ionis-FB-LRX is not the worst outcome that could befall it. After all, Glaxo had paid $35m seven years ago to ... Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up - Nasdaq Lookout for Price Target? United Technologies Corporation (UTX), Ionis ... - StockNewsJournal [...]
Mon, Aug 14, 2017 12:56:00 PM, Continue reading at the source
Ionis Pharmaceuticals results: The raw numbers Motley Fool - Aug 11, 2017 The rest of the revenue came from the usual mix of milestone payments and licensing fees from Ionis' various partners. In May, the company reported positive results for its NEURO-TTR phase 3 trial testing inotersen in patients with hereditary TTR ... Ionis to Independently Advance Inotersen and IONIS-FB-L Rx - PR Newswire (press release) Most Recent Analysts Ratings Ionis Pharmaceuticals, Inc. (IONS) - ExpressNewsline [...]
Fri, Aug 11, 2017 8:03:00 PM, Continue reading at the source
Ionis Pharmaceuticals (IONS) Misses on Q2 Earnings Nasdaq - Aug 8, 2017 Carlsbad, CA-based Ionis Pharmaceuticals, Inc. IONS is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies. Ionis Provides Improved 2017 Guidance Following Strong Financial Performance - PR Newswire (press release) Ionis Pharmaceuticals Inc (IONS): Time For A Financial Health Check - Simply Wall St [...]
Tue, Aug 08, 2017 12:00:00 PM, Continue reading at the source
Revenue Approximations Analysis: Extended Stay America, Inc. (STAY), Ionis ... StockNewsJournal - Jul 28, 2017 The average of this ratio is -8.82 for the industry and sector's best figure appears -8.37. Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals Inc. - Receive News & Ratings Daily - TheOlympiaReport Ionis Pharmaceuticals, Inc. (IONS) Upgraded by Zacks Investment Research to “Buy” - Week Herald [...]
Fri, Jul 28, 2017 11:48:00 AM, Continue reading at the source
Ionis Pharmaceuticals to Hold Second Quarter 2017 Financial Results Webcast PR Newswire (press release) - Jul 25, 2017 CARLSBAD, Calif., July 25, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, August 8 at 11:30 a.m. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Flashed an Extremely Rare 'Buy ... - StockNewsGazette Ionis Pharmaceuticals Inc. (IONS) Moves Lower on Volume Spike for July 25 - [...]
Tue, Jul 25, 2017 11:03:00 AM, Continue reading at the source